/biz/ - Business & Finance

Alright gay boys, after some DD I'm pretty sure that HTBX is gonna make a spike in the days leading up to and possibly on the 30th. Here's why.

They're releasing data on phase 2 trials of a bladder cancer drug on the 30th. http://ir.heatbio.com/press-releases/detail/540/heat-biologics-to-present-topline-hs-410-phase-ii-bladder

After looking up the conference and poster they're presenting, the abstracts and summary says:

"Results: Vesigenurtacel-L treatment was well tolerated with no vaccine-related SAEs; primary AEs were mild, most commonly transient injection site reactions. "

"Conclusions: The combination of vesigenurtacel-L and BCG is well-tolerated with preliminary evidence of synergistic effect and immunologic responses that are consistent with vaccine mechanism of action. Vesigenurtacel-L warrants further investigation as a potential treatment for NMIBC."

Source: http://suonet.org/meetings/upcoming-meetings/2016-suo-annual-meeting/online-program-viewer.aspx (look up poster #21, type in "Vesigenurtacel" and it should pop up)

Now I think some of this is priced in because of the price spike on the 16 but I'm not sure if that's because people actually did the DD and found this summary on the article or if they just were speculating on the press release. Either way, it's dropped down to $1.42. There's also a bit of a lull in terms of volume too.

52 week range is 0.40-1.43.

Unless I'm reading this wrong I'm assuming they're gonna have a press release after the poster presentation saying that the drug showed positive results for the trial.

Thoughts?